Ascendis Pharma Commences Public Offering Of $300M Of ADSs
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $205
Cantor Fitzgerald analyst Joshua Schimmer maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and adjusts the target price from $165 to $205.According to TipRanks data, the analyst has a
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $180
J.P. Morgan analyst Jessica Fye maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and adjusts the target price from $165 to $180.According to TipRanks data, the analyst has a success rate
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $190
Oppenheimer analyst Leland Gershell maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and adjusts the target price from $180 to $190.According to TipRanks data, the analyst has a success
Ascendis Pharma Is Maintained at Buy by Citigroup
Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $179
Jefferies analyst Kelly Shi maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and adjusts the target price from $174 to $179.According to TipRanks data, the analyst has a success rate of 43.